Global Hunter Securities initiates coverage on Corcept Therapeutics. (Nasdaq: CORT) with a Buy rating. PT $5.

Global analyst says, "CORLUX ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE